Compare SVC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | RIGL |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.2M | 911.8M |
| IPO Year | 1995 | 2000 |
| Metric | SVC | RIGL |
|---|---|---|
| Price | $6.28 | $51.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $12.19 | ★ $63.00 |
| AVG Volume (30 Days) | ★ 2.5M | 176.0K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | 26.95 | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | ★ $1,814,838,000.00 | $294,282,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | $3.31 | $21.95 |
| P/E Ratio | ★ N/A | $36.74 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $1.13 | $24.84 |
| 52 Week High | $9.02 | $52.61 |
| Indicator | SVC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 50.97 |
| Support Level | $5.65 | $44.83 |
| Resistance Level | $6.87 | $50.19 |
| Average True Range (ATR) | 0.25 | 1.73 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 56.41 | 47.44 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its segments hotel investment unit, and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza, Hyatt Place, and others.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.